This document is a guide defining requirements for quality and safety for malaria rapid diagnostic testing services to safeguard the quality of the results, the safety of the operators and patients and that of the environment for use by national malaria control programmes, regulators, implementers a...nd rapid diagnostic providers.
more
This new guidance aims to support programme implementers, coordinators and others in humanitarian settings in their actions to counter suicide and self-harm in humanitarian contexts and to save lives.
The identification of Priority Areas for Multisectoral Interventions (PAMIs, sometimes referred to as ‘hotspots’) for cholera control is among the first steps for a cholera-affected country to develop or revise a National Cholera Plan (NCP) for cholera control. PAMI identification is critical to... maximize the potential impact of NCP implementation on cholera control.
more
The approach is in line with two of the five objectives outlined in the Every Newborn Action Plan (ENAP): Strategic Objective 2 – Improve the quality of maternal and newborn care; and Strategic Objective 5 – Count every newborn through measurement, programme-tracking and accountability to genera...te data for decision-making and action.
more
L’objectif de ces lignes directrices est de présenter l’ensemble complet des recommandations et des énoncés de meilleures pratiques de l’OMS en matière d’avortement
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
This document is also available in Arabic and Portuguese.
Reach the Unreached - FIND, TREAT, CURE TB, SAVE LIVES
WHO Secretariat Information paper July 2016
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D ac...tivities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.
more